News Daily News Patients With Obesity Get Biggest Benefit from Evolocumab: FOURIER Michael O'Riordan December 12, 2025
News Conference News AHA 2025 Evolocumab Cuts MACE Risk in Patients Without Prior MI, Stroke: VESALIUS-CV Michael O'Riordan November 08, 2025
News Industry News SMT’s Supraflex Cruz Shows Consistent and Robust Clinical Outcomes Across Key Global Studies Presented at TCT 2025 October 29, 2025
News Conference News ESC 2025 High hs-CRP Linked to More CVD Events in Women Lacking Traditional Risk Factors Caitlin E. Cox August 29, 2025
News Daily News Coronary Sinus Reducer ‘Promising’ for Refractory Angina: Meta-analysis Todd Neale August 13, 2025
News Daily News Heart Disease Deaths Decline Over Last 50 Years, but Not Across the Board Michael O'Riordan June 25, 2025
News Daily News Knowledge of Genetic Risk for CAD Bolsters Prevention, Reduces MACE Caitlin E. Cox April 23, 2025
News Daily News ISCHEMIA: No Clinical Event Reduction With Invasive Strategy in CTO Patients Michael O'Riordan March 26, 2025
News Daily News Coronary Sinus Reducer Overlooked in Review of Stable Angina Treatments Michael O'Riordan January 03, 2025
News Conference News TCT 2024 Colchicine Surprise: No Help Post-MI, Large CLEAR SYNERGY Trial Shows Michael O'Riordan October 29, 2024
News Opinion Editor's Corner TCT 2024 What’s Going to Be Big at TCT 2024? Michael O'Riordan October 17, 2024
News Conference News ESC 2024 ESC’s 2024 CCS Guidelines Embrace New Data, Smooth Old Tensions Michael O'Riordan September 17, 2024
News Conference News ESC 2024 ABYSS: Safety Signal Seen When Beta-blockers Stopped in Post-MI Patients Michael O'Riordan August 30, 2024
News Conference News EuroPCR 2024 NOW PUBLISHED - Latest TAVI vs Surgery Trial Raises Eyebrows in Aortic Stenosis Plus CAD Michael O'Riordan May 14, 2024
News Daily News TAVI Outcomes Linked to LV Recovery in Patients With Severe Dysfunction Michael O'Riordan May 06, 2024
News Conference News ACC 2024 Another Beta-blocker Blow: REDUCE-AMI Confirms No Benefit After Acute MI Michael O'Riordan April 07, 2024
News Daily News Mechanism’s Mojo: ‘Obvious’ CV Therapies More Likely to Be Seen as Effective Michael O'Riordan February 23, 2024